BNC105: Phase I/II data

Data from 15 evaluable patients with partially platinum-sensitive ovarian cancer in first or second relapse in the dose-escalation Phase I portion of an open-label, international Phase I/II trial showed that 12 or 16 mg/m 2 BNC105 plus gemcitabine and carboplatin led to a "positive" response according to RECIST and/or Gynecologic Cancer Intergroup (GCIG) CA125 criteria in 10 patients. The Phase II portion of the trial is evaluating gemcitabine plus carboplatin with or without the recommended dose of 12 mg/m 2 BNC105 in about 110 patients. In the BNC105 arms, patients receive BNC105 on days 2 and 9 in combination with gemcitabine on days 1 and 8 and carboplatin on day 1 of a 21-day cycle for up to 6 cycles, followed by BNC105 alone for up to 6 cycles. The Australian and New Zealand Gynaecological Oncology Group, the University of Sydney and the Hoosier Oncology Group are conducting the trial. Bionomics could not be reached for next steps. ...